Bidirectional crosstalk along the gut-liver axis controls gastrointestinal health and disease
and exploits environmental and host mediators. Nutrients, microbial antigens, metabolites …

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …

Management of primary or secondary sclerosing cholangitis is challenging. These Clinical
Practice Guidelines have been developed to provide practical guidance on debated topics …

Developments in high-throughput microbial genomic sequencing and other systems biology
techniques have given novel insight into the potential contribution of the gut microbiota to …

Although faecal microbiota transplantation (FMT) has a well-established role in the treatment
of recurrent Clostridioides difficile infection (CDI), its widespread dissemination is limited by …

Background Faecal microbiota transplantation (FMT) is an effective treatment in C. difficile
infection (CDI) and is currently being investigated in other diseases. There is concern …

Inflammatory bowel disease (IBD) is an inflammatory disease of the gastrointestinal tract, the
incidence of which has rapidly increased worldwide, especially in developing and Western …

Fecal microbiota transplantation (FMT) is the introduction (transplantation) of gut microbiota
obtained from the faeces of a healthy donor into the patient's gastrointestinal tract. Most …

Primary sclerosing cholangitis (PSC) offers unique opportunities to explore the gut–liver axis
owing to the close association between liver disease and colonic inflammation. It is well …

The human body is home to a variety of micro-organisms. Most of these microbial
communities reside in the gut and are referred to as gut microbiota. Over the last decades …